Department of Pediatrics/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), West China Second University Hospital, Sichuan University, Chengdu, 610041, China.
NHC Key Laboratory of Chronobiology (Sichuan University), Chengdu, 610041, China.
Breast Cancer Res. 2024 Jul 3;26(1):110. doi: 10.1186/s13058-024-01869-8.
Breast cancer (BC) is a highly prevalent malignancy worldwide, with complex pathogenesis and treatment challenges. Research reveals that methyltransferase-like 3 (METTL3) is widely involved in the pathogenesis of several tumors through methylation of its target RNAs, and its role and mechanisms in BC are also extensively studied. In this review, we aim to provide a comprehensive interpretation of available studies and elucidate the relationship between METTL3 and BC. This review suggests that high levels of METTL3 are associated with the pathogenesis, poor prognosis, and drug resistance of BC, suggesting METTL3 as a potential diagnostic or prognostic biomarker and therapeutic target. Collectively, this review provides a comprehensive understanding of how METTL3 functions through RNA methylation, which provides a valuable reference for future fundamental studies and clinical applications.
乳腺癌（BC）是一种在全球范围内普遍存在的高度恶性肿瘤，具有复杂的发病机制和治疗挑战。研究表明，甲基转移酶样 3（METTL3）通过对其靶 RNA 的甲基化广泛参与多种肿瘤的发病机制，其在 BC 中的作用和机制也得到了广泛研究。在这篇综述中，我们旨在对现有研究进行全面解读，并阐明 METTL3 与 BC 之间的关系。本综述表明，METTL3 水平高与 BC 的发病机制、不良预后和耐药性有关，提示 METTL3 作为一种潜在的诊断或预后生物标志物和治疗靶点。总的来说，本综述全面了解了 METTL3 通过 RNA 甲基化发挥作用的机制，为未来的基础研究和临床应用提供了有价值的参考。
Zotero 插件